XML 41 R32.htm IDEA: XBRL DOCUMENT v3.25.4
Stockholders' Equity - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Common Stock, Shares Authorized 400,000,000 400,000,000
Common Stock, Par Value $ 0.0001 $ 0.0001
Common Stock, Shares Outstanding 9,314,130 3,420,906
Common Stock, Shares issued 9,314,130 3,420,906
Issuance of preferred shares 10,000,000  
Preferred stock, par value $ 0.0001  
Preferred Stock, Undesignated Shares Authorized 4,818,654 4,818,654
Preferred Stock convertible into share of common stock 1 1
Weighted average remaining contractual life options exercisable 8 years 11 months 12 days  
Compensation Expense $ 18,800,000 $ 1,000,000
Unrecognized Compensation Costs $ 14,700,000  
Weighted average remaining vesting period 1 year 5 months 19 days  
March 2025 Private Placement Financing [Member] | Pre-Funded Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise price $ 0.01  
Warrant to purchase share of common stock 378,346  
Common stock shares 3,760,726  
Offering Price $ 6.04  
Common stock warrant $ 6.03  
Gross proceeds form warrant $ 25,000,000  
Agent fees and direct offering expenses 23,200,000  
Fair value allocated 2,300,000  
Pre-funded warrants $ 22,700,000  
August 2024 Private Placement Financing [Member] | Pre-Funded Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Exercise price $ 0.01  
Warrant to purchase share of common stock 1,450,661  
Common stock shares 31,882,671  
Warrant purchase 16,666,666  
Offering Price $ 3  
Common stock warrant $ 2.99  
Gross proceeds form warrant $ 99,700,000  
Agent fees and direct offering expenses 92,300,000  
Fair value allocated 3,200,000  
Warrant 27,100,000  
Pre-funded warrants $ 69,400,000  
February 2024 Offering 1 [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Common stock shares 1,178,740  
Warrant purchase 3,200,000  
Offering Price $ 5.65  
Common stock warrant $ 5.649  
Gross proceeds form warrant $ 9,000,000  
Agent fees and direct offering expenses 8,000,000  
Fair value allocated 900,000  
Warrant 5,700,000  
Pre-funded warrants $ 2,400,000  
February 2024 Offering 1 [Member] | Pre-Funded Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrant to purchase share of common stock 421,260  
February 2024 [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Warrant to purchase share of common stock 3,200,000  
Offering Price $ 5.65  
Weighted average remaining contractual life options exercisable 5 years  
Fair value allocated $ 5,700,000  
Risk-free interest rate 4.12%  
Expected dividend yield 0.00%  
Dividend Yield 131.87%  
August 2024 Warrants [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Issued unregistered warrants to purchase shares of common stock 16,666,666  
Offering Price $ 4.5  
Weighted average remaining contractual life options exercisable 1 year 9 months 18 days  
Fair value allocated $ 27,100,000  
Risk-free interest rate 3.83%  
Expected dividend yield 0.00%  
Dividend Yield 177.27%  
2022 Stock Incentive Plan    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of shares of common stock authorized for issuance 8,337,252  
Shares remained available for issuance 1,721,121  
Series A Stock Plan    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Issuance of preferred shares 5,181,346  
Prefered Stock, Shares Outstanding 210 210
Inducement Stock Options [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Compensation Expense $ 400,000 $ 100,000
Unrecognized Compensation Costs $ 1,100  
Inducement Stock Options [Member] | President and Chief Executive Officer [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of shares of common stock authorized for issuance 157  
Stock Options Description This award vested in four equal installments beginning on the first anniversary of the date of issuance, subject to continued employment. The option has a 10-year term and an exercise price of $3,152 per share, the July 6, 2021 closing price of our common stock.  
Stock Option Award Granted 403,000  
Risk-free interest rate 1.13%  
Dividend Yield 0.00%  
Volatility Factor Rate 99.36%  
Expected Life 7 years  
Inducement Stock Options [Member] | Chief Medical Officer [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Stock Options Description This employment inducement stock option was awarded in accordance with the employment inducement award exemption provided by Nasdaq Listing Rule 5635(c)(4) and was therefore not awarded under the Company’s stockholder approved equity plan. The option award will vest as follows: 25% upon initiation of a Phase 3 trial; 25% upon database lock; 25% upon acceptance for review of an investigational NDA; and 25% upon approval. The option has a 10-year term and an exercise price of $2,848 per share, the January 15, 2021 closing price of our common stock, as adjusted for the subsequent reverse stock splits.  
Stock Option Award Granted 157  
Risk-free interest rate 11.00%  
Dividend Yield 0.00%  
Volatility Factor Rate 103.94%  
Expected Life 10 years  
Estimated Fair Value Of The Inducement Stock Option Award Granted $ 403,000  
First Inducement Stock Options    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Number of shares of common stock authorized for issuance 250,000  
Stock Options Description The option award vests in four equal annual installments beginning on the first anniversary of the date of issuance, subject to the employee's continued employment with the Company through each applicable vesting date. The option has a 10-year term and an exercise price of $6.45 per share, the January 21, 2025 closing price of the Company’s common stock.  
Stock Option Award Granted 1,400,000  
Risk-free interest rate 4.49%  
Dividend Yield 0.00%  
Volatility Factor Rate 123.41%  
Expected Life 6 years